Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tevogen Bio Holdings Inc. - Warrant (NQ:TVGNW)

0.0579 UNCHANGED
Streaming Delayed Price Updated: 3:13 PM EDT, Mar 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 307,087
Open 0.0495
Bid (Size) 0.0443 (27)
Ask (Size) 0.0679 (5)
Prev. Close 0.0579
Today's Range 0.0444 - 0.0580
52wk Range 0.0099 - 0.1499
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast
From Tevogen Bio Inc
Via GlobeNewswire
These stocks are gapping in today's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Wednesday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill

Performance

YTD
-3.5%
-3.5%
1 Month
-15.1%
-15.1%
3 Month
-1.9%
-1.9%
6 Month
+288.6%
+288.6%
1 Year
-29.8%
-29.8%

More News

Read More
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan
From Tevogen Bio Inc
Via GlobeNewswire
Top movers in Thursday's session
Via Chartmill
Which stocks are gapping on Thursday?
Via Chartmill
Monday's session: top gainers and losers
Via Chartmill
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel
From Tevogen Bio Inc
Via GlobeNewswire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
Friday's pre-market session: top gainers and losers
Via Chartmill
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Reinforces Commitment to Retention of Equity Capital and Long-Term Vision
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Congratulates RFK Jr. on His Confirmation as Secretary of the HHS; Echoes Commitment to Innovation and Affordability for Americans
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Meets BARDA TechWatch Team, Highlighting ExacTcell™ Technology’s Potential as a Scalable Medical Countermeasure
From Tevogen Bio Inc
Via GlobeNewswire
Stay updated with the stocks that are on the move in today's pre-market session.
Via Chartmill
Tevogen Bio Enters Agreement to Receive Up To $10 Million of Non-Dilutive Grant Funding
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio CEO Congratulates Lynne Patton on Being Appointed Deputy Assistant to the President and Director of Minority Outreach
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Broadens Relationship with Microsoft to Deepen Artificial Intelligence Collaboration and Develop PredicTcell Technology on Azure
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio to Host Panel Discussions “AI In Biopharma: Next Frontier of Medical Innovation” and “Pioneering the Economics of Health: Balancing Access and Outcomes” During J.P. Morgan Healthcare Conference
From Tevogen Bio Inc
Via GlobeNewswire
Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference
From Tevogen Bio Inc
Via GlobeNewswire

Frequently Asked Questions

Is Tevogen Bio Holdings Inc. - Warrant publicly traded?
Yes, Tevogen Bio Holdings Inc. - Warrant is publicly traded.
What exchange does Tevogen Bio Holdings Inc. - Warrant trade on?
Tevogen Bio Holdings Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for Tevogen Bio Holdings Inc. - Warrant?
The ticker symbol for Tevogen Bio Holdings Inc. - Warrant is TVGNW on the Nasdaq Stock Market
What is the current price of Tevogen Bio Holdings Inc. - Warrant?
The current price of Tevogen Bio Holdings Inc. - Warrant is 0.0579
When was Tevogen Bio Holdings Inc. - Warrant last traded?
The last trade of Tevogen Bio Holdings Inc. - Warrant was at 03/28/25 03:13 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.